343 related articles for article (PubMed ID: 33001306)
1. LI-RADS category 5 hepatocellular carcinoma: preoperative gadoxetic acid-enhanced MRI for early recurrence risk stratification after curative resection.
Wei H; Jiang H; Zheng T; Zhang Z; Yang C; Ye Z; Duan T; Song B
Eur Radiol; 2021 Apr; 31(4):2289-2302. PubMed ID: 33001306
[TBL] [Abstract][Full Text] [Related]
2. Hepatocellular carcinoma: preoperative gadoxetic acid-enhanced MR imaging can predict early recurrence after curative resection using image features and texture analysis.
Ahn SJ; Kim JH; Park SJ; Kim ST; Han JK
Abdom Radiol (NY); 2019 Feb; 44(2):539-548. PubMed ID: 30229421
[TBL] [Abstract][Full Text] [Related]
3. Gadoxetic acid-enhanced MRI as a predictor of recurrence of HCC after liver transplantation.
Lee S; Kim KW; Jeong WK; Kim MJ; Choi GH; Choi JS; Song GW; Lee SG
Eur Radiol; 2020 Feb; 30(2):987-995. PubMed ID: 31471754
[TBL] [Abstract][Full Text] [Related]
4. The role of lesion hypointensity on gadobenate dimeglumine-enhanced hepatobiliary phase MRI as an additional major imaging feature for HCC classification using LI-RADS v2018 criteria.
Zhang Y; Tang W; Xie S; Chen J; Zhang L; Rong D; Kuang S; He B; Wang J
Eur Radiol; 2021 Oct; 31(10):7715-7724. PubMed ID: 33782766
[TBL] [Abstract][Full Text] [Related]
5. Can LI-RADS imaging features at gadoxetic acid-enhanced MRI predict aggressive features on pathology of single hepatocellular carcinoma?
Wei H; Jiang H; Liu X; Qin Y; Zheng T; Liu S; Zhang X; Song B
Eur J Radiol; 2020 Nov; 132():109312. PubMed ID: 33022551
[TBL] [Abstract][Full Text] [Related]
6. Prognosis after Curative Resection of Single Hepatocellular Carcinoma with A Focus on LI-RADS Targetoid Appearance on Preoperative Gadoxetic Acid-Enhanced MRI.
Moon JY; Min JH; Kim YK; Cha D; Hwang JA; Ko SE; Choi SY; Yun EJ; Kim SW; Won HJ
Korean J Radiol; 2021 Nov; 22(11):1786-1796. PubMed ID: 34402243
[TBL] [Abstract][Full Text] [Related]
7. Hepatobiliary MRI as novel selection criteria in liver transplantation for hepatocellular carcinoma.
Kim AY; Sinn DH; Jeong WK; Kim YK; Kang TW; Ha SY; Park CK; Choi GS; Kim JM; Kwon CHD; Joh JW; Kim MJ; Sohn I; Jung SH; Paik SW; Lee WJ
J Hepatol; 2018 Jun; 68(6):1144-1152. PubMed ID: 29410377
[TBL] [Abstract][Full Text] [Related]
8. Hepatobiliary phase of gadoxetic acid-enhanced MRI in patients with HCC: prognostic features before resection, ablation, or TACE.
Bae JS; Kim JH; Lee DH; Kim JH; Han JK
Eur Radiol; 2021 Jun; 31(6):3627-3637. PubMed ID: 33211146
[TBL] [Abstract][Full Text] [Related]
9. Long-term evolution of LR-2, LR-3 and LR-4 observations in HBV-related cirrhosis based on LI-RADS v2018 using gadoxetic acid-enhanced MRI.
Xing F; Zhang T; Miao X; Lu J; Du S; Jiang J; Xing W
Abdom Radiol (NY); 2023 Dec; 48(12):3703-3713. PubMed ID: 37740759
[TBL] [Abstract][Full Text] [Related]
10. Peritumoral decreased uptake area of gadoxetic acid enhanced magnetic resonance imaging and tumor recurrence after surgical resection in hepatocellular carcinoma: A STROBE-compliant article.
Shin SK; Kim YS; Shim YS; Choi SJ; Park SH; Jung DH; Kwon OS; Choi DJ; Kim JH
Medicine (Baltimore); 2017 Aug; 96(33):e7761. PubMed ID: 28816953
[TBL] [Abstract][Full Text] [Related]
11. Prognostic factors of gadoxetic acid-enhanced MRI for postsurgical outcomes in multicentric hepatocellular carcinoma.
Kim SS; Lee S; Kim MJ
Eur Radiol; 2021 May; 31(5):3405-3416. PubMed ID: 33146795
[TBL] [Abstract][Full Text] [Related]
12. Hepatocellular carcinoma: Can LI-RADS v2017 with gadoxetic-acid enhancement magnetic resonance and diffusion-weighted imaging improve diagnostic accuracy?
Zhang T; Huang ZX; Wei Y; Jiang HY; Chen J; Liu XJ; Cao LK; Duan T; He XP; Xia CC; Song B
World J Gastroenterol; 2019 Feb; 25(5):622-631. PubMed ID: 30774276
[TBL] [Abstract][Full Text] [Related]
13. The role of gadoxetic acid-enhanced MRI features for predicting microvascular invasion in patients with hepatocellular carcinoma.
Yang H; Han P; Huang M; Yue X; Wu L; Li X; Fan W; Li Q; Ma G; Lei P
Abdom Radiol (NY); 2022 Mar; 47(3):948-956. PubMed ID: 34962593
[TBL] [Abstract][Full Text] [Related]
14. Can modified LI-RADS increase the sensitivity of LI-RADS v2018 for the diagnosis of 10-19 mm hepatocellular carcinoma on gadoxetic acid-enhanced MRI?
Xie S; Zhang Y; Chen J; Jiang T; Liu W; Rong D; Sun L; Zhang L; He B; Wang J
Abdom Radiol (NY); 2022 Feb; 47(2):596-607. PubMed ID: 34773467
[TBL] [Abstract][Full Text] [Related]
15. Prediction for Aggressiveness and Postoperative Recurrence of Hepatocellular Carcinoma Using Gadoxetic Acid-Enhanced Magnetic Resonance Imaging.
Lu M; Qu Q; Xu L; Zhang J; Liu M; Jiang J; Shen W; Zhang T; Zhang X
Acad Radiol; 2023 May; 30(5):841-852. PubMed ID: 36577606
[TBL] [Abstract][Full Text] [Related]
16. LI-RADS v2014 categorization of hepatocellular carcinoma: Intraindividual comparison between gadopentetate dimeglumine-enhanced MRI and gadoxetic acid-enhanced MRI.
Song JS; Choi EJ; Hwang SB; Hwang HP; Choi H
Eur Radiol; 2019 Jan; 29(1):401-410. PubMed ID: 29922928
[TBL] [Abstract][Full Text] [Related]
17. Prognostic value of LI-RADS category on gadoxetic acid-enhanced MRI and 18F-FDG PET-CT in patients with primary liver carcinomas.
Min JH; Kim SH; Hwang JA; Hyun SH; Ha SY; Choi SY; Kim SW; Kim HS
Eur Radiol; 2021 Jun; 31(6):3649-3660. PubMed ID: 33211142
[TBL] [Abstract][Full Text] [Related]
18. Extracellular contrast-enhanced MRI with diffusion-weighted imaging for HCC diagnosis: prospective comparison with gadoxetic acid using LI-RADS.
Cha DI; Choi GS; Kim YK; Kim JM; Kang TW; Song KD; Ahn SH
Eur Radiol; 2020 Jul; 30(7):3723-3734. PubMed ID: 32128620
[TBL] [Abstract][Full Text] [Related]
19. Suboptimal performance of LI-RADS v2018 on gadoxetic acid-enhanced MRI for detecting hepatocellular carcinoma in liver transplant candidates.
Oh NE; Choi SH; Kim S; Lee H; Jang HJ; Byun JH; Won HJ; Shin YM
Eur Radiol; 2024 Jan; 34(1):465-474. PubMed ID: 37532900
[TBL] [Abstract][Full Text] [Related]
20. Preoperative gadoxetic acid-enhanced MRI for predicting microvascular invasion in patients with single hepatocellular carcinoma.
Lee S; Kim SH; Lee JE; Sinn DH; Park CK
J Hepatol; 2017 Sep; 67(3):526-534. PubMed ID: 28483680
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
